Kyoto University

National Institute of Radiological Sciences

Nidec Corporation

Riken Corporation

National Institutes for Quantum and Radiological Science and Technology

Ryosuke Takahashi

Haruhisa Inoue

Tetsuya Suhara

Hiroki Takeuchi

Makoto Higuchi

Bin Ji

Hiroshi Kobayashi

Norio Nakatsuji

Takeshi Ohiro

Motonari Uesugi

Takayuki Kondo

Kazuhiro Aiba

Nobuhisa Iwata

Shiho Kitaoka

Shigeyoshi Itohara

Gaku Murakami

Yasuyuki Asai

Yuji Amagai

Kayoko Tsukita

Takuji Iwasato

Toshitsugu Yamamoto

Takuya Ogawa

Masashi Asai

Ayako Asai

A motor unit having a motor shaft, and a speed reduction mechanism connected to the motor shaft are included. The speed reduction mechanism includes a sun gear unit disposed on the motor shaft, planetary gear units meshing with the sun gear unit and arranged in the circumferential direction, a carrier at least a part of which surrounds the planetary gear units, and an output unit connected to the planetary gear units. The carrier includes a first cylindrical portion disposed outward of and above the sun gear unit and extending in the axial direction. The first cylindrical portion rotatably supports the output unit via a bearing, and the bearing is at least partly disposed radially inward of the radially outer end of the planetary gear unit.

Drive device and movable body

The present invention provides a prophylactic or therapeutic agent for amyotrophic lateral sclerosis, containing a 1,3-diphenylurea derivative or multikinase inhibitor.

Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

Vaccine for treatment of tautopathy

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

It is intended to provide an agent for regulating axon extension during neuranagenesis by regulating ephrin-Eph receptor signaling mechanisms and to provide a mouse having abnormal ephrin-Eph receptor signaling mechanisms. The present invention relates to a regulator of axon extension, comprising an agent for promoting or suppressing the function of &#x3b1;-chimerin, and to a miffy (mfy) mouse derived from a B6 strain, which displays autosomal recessive inheritance of an abnormal walking trait exhibiting a hopping gait with left-right synchronized movement of limbs and has mutation in an &#x3b1;-chimerin gene.

Regulator of ephrin-Eph receptor signaling and mouse having abnormal ephrin-Eph receptor signaling mechanisms

Growing community of inventors

Kyoto, Japan

Ryosuke Takahashi